Genentech
{{#badges: GlobalCorpWiki}}
Genentech, Inc. is a pharmaceutical company and one of the world's most financially successful and biotechnology corporations. The Swiss drug company Roche, which previously owned a majority of stock in the San Francisco based firm, took full ownership in 2009. Genentech has three drugs that are billion-dollar sellers: Rituxan, for non-Hodgkin's lymphoma; Avastin, for colorectal, non-small cell lung cancers, and treats macular degeneration; and Herceptin for breast cancer. It also manufactures the lung cancer drug Tarceva. Major customers for its drugs are AmerisourceBergen, Cardinal Health, and McKesson. In the fiscal year ending in December of 2008, Genentech had sales of 13.4 billion dollars and had 11,174 employees. [1]
According to its website, the company is "considered the founder of the biotechnology industry." The company has "been delivering on the promise of biotechnology for more than 30 years, using human genetic information to discover, develop, commercialize and manufacture biotherapeutics that address significant unmet medical needs." [2]
Contents
Animal testing
Genentech does animal testing.
Animals by species, numbers & location
- San Francisco, California [3]
Facility information, progress reports & USDA-APHIS reports
For copies of this facility's U.S. Department of Agriculture-Animal Plant Health Inspection (APHIS) reports, other information and links, see also Stop Animal Experimentation Now!: Facility Reports and Information. This site lists each of the 50 states; each state's name links to biomedical research facilities in that state and to PDF copies of government documents where the facilities must report their animal usage.
Selected staff & board
- Ian Clark - CEO
- Pascal Soriot - CEO
- Steve Krognes - CFO [4]
- Laura A. Leber
- J. Richard Munro - CEO (ret.) [5]
- William D. Young - Former COO - [6]
- Amo Houghton
Board
- Herbert W. Boyer, Ph.D., Vice-Chairman of the Board - Allergan, Inc.
- William M. Burns
- Erich Hunziker
- Jonathan K.C. Knowles, Ph.D.
- Arthur D. Levinson, Ph.D. - Board - Apple Computer, Inc.
- Debra L. Reed - Board - Halliburton Company
- Charles A. Sanders, M.D. [7]
Executive compensation (2007)
- Arthur D. Levinson, Chairman, CEO - $17,124,025 (also exercised $66,268,100 in options)[8]
- Susan D. Desmond-Hellmann, Divisional President - $7,820,142 (also exercised $33,465,041 in options)[9]
- David A. Ebersman - CEO - $4,030,747[10]
- Stephen G. Juelsgaard - Executive VP - $4,896,340 (also exercised $24,980,534 in options)[11]
- Richard H. Scheller, Divisional Executive VP - $4,992,779 (also exercised $10,880,395 in options)[12]
Political Contributions
Genentech gave almost $400,000 to candidates in the 2008 election cycle through its political action committee.[13] This is almost twice as much as in 2006, when it donated $201,500 to federal candidates in the 2006 election through its political action committee - 38% to Democrats and 57% to Republicans.[14]
Lobbying
According to Lisa Graves of the Center for Media and Democracy a search of the Lobby Disclosure Act database for "Genentech" spending in 2009 reveals that the company spent over $3.7 million in lobbying Congress on health care issues in the first three quarters on the year, including over $2.1 million itself and the remainder on lobbyists such as the American Continental Group.[15] Genentech's lobbying made the news after its talking points showed up in the statements that several Members of Congress submitted to the Congressional Record, the official journal of congressional proceedings, during the 2009 debate over health care reforms. [16]
Contact
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080
Phone: 650-225-1000
Fax: 650-225-6000
Web address: http://www.gene.com
Articles & sources
Sourcewatch articles
References
- ↑ Company Description: Genentech, Hoovers, accessed December 2009
- ↑ About Us: Leading the Biotechnology Industry, Genentech, accessed July 2007
- ↑ Research Facilities: Genentech, Inc., San Francisco, California, Humane Society of the United States, accessed December 2009
- ↑ Company Description: Genentech, Hoovers, accessed December 2009
- ↑ Board of Directors, Points of Light Foundation, accessed July 2007
- ↑ Board of Directors, Biogen Idec, accessed July 2007
- ↑ Board of Directors, Genentech, accessed July 2007
- ↑ Arthur D Levinson, Forbes, accessed December 2007.
- ↑ Susan D Desmond-Hellmann, Forbes, accessed December 2007.
- ↑ David A Ebersman, Forbes, accessed December 2007.
- ↑ Stephen G Juelsgaard, Forbes, accessed December 2007.
- ↑ Richard H Scheller, Forbes, accessed December 2007
- ↑ [1], "CampaignMoney.com," accessed on November 15, 2009.
- ↑ 2006 PAC Summary Data, Open Secrets, accessed December 2007.
- ↑ Lisa Graves Biotech's Ghostwriting Animates Congressional Speeches on Health Reform, Center for Media and Democracy, November 15, 2009.
- ↑ Robert Pear In House, Many Spoke with One Voice: Lobbyists, New York Times, November 2009
